Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, January 18, 2017
Eisai to Participate in Access Accelerated, Global Partnership to Address Rise of Non-Communicable Diseases
Monday, January 16, 2017
Transfer of Rights to Insomia Treatment / Anaesthesia Induction Agent Flunitrazepam in Japan
Thursday, January 12, 2017
Eisai to Launch Medication Administration Support Device
Thursday, January 5, 2017
Eisai Acquires All Global Development and Marketing Rights for Chronic Weight Management Treatment Lorcaserin
Thursday, December 22, 2016
Eisai and Keio University to Establish a New Industry-Academia Collaboration Site
Tuesday, December 20, 2016
Anticancer Agent Treakisym Approved in Japan for Additional Indication as First-Line Treatment for Low-Grade B-Cell Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
Friday, November 18, 2016
U.S. FDA Grants Fast Track Designation for the Development of Eisai's Bace Inhibitor E2609 for Early Alzheimer's Disease
Friday, November 4, 2016
U.K. NICE Recommends Anticancer Agent Halaven as Treatment for Advanced Breast Cancer
Monday, October 31, 2016
Enrollment Commences in Phase III Clinical Study of Eisai's BACE Inhibitor E2609 in Early Alzheimer's Disease
Thursday, October 13, 2016
Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide

Copyright © 2018 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 800 291 0906 | Beijing: +86 10 8405 3688 | Hong Kong: +852 2217 2912 | Singapore: +65 6304 8926 | Tokyo: +81 3 6721 7212

Connect With us: